Mahamaya Lifesciences posted robust FY26 results with revenue up 24.5% to Rs 328.87 crore and net profit rising 29% to Rs 16.52 crore. The company significantly improved its balance sheet, cutting its net debt-to-equity ratio to 0.74x. A key highlight is the upcoming Dahej plant expansion, targeted for pilot production by December 2026 to boost technical manufacturing self-reliance.
Mahamaya Lifesciences FY26 Profit Rises 29% to Rs 16.52 Crore
Revenue reached Rs 328.87 crore, a 24.5% increase year-on-year.
EBITDA climbed 32.6% to Rs 34.26 crore, reflecting stronger operational efficiency.
Reader Takeaway: Strong double-digit earnings growth coupled with a healthier balance sheet; monitor the Dahej facility execution timeline.
What just happened
Mahamaya Lifesciences released its financial performance for FY2026, demonstrating broad-based growth. The company reported a 24.5% jump in revenue and a 29% rise in Profit After Tax (PAT). Operating margins improved alongside earnings, as the firm benefited from a wider product portfolio and increased business volumes across its international markets.
Why this matters
The company’s ability to scale revenue while simultaneously improving its balance sheet is a positive indicator for investors. The net debt-to-equity ratio improved substantially to 0.74x from 1.18x, suggesting lower financial risk and greater flexibility for future growth initiatives.
Operational Roadmap: Dahej Facility
Management provided a clear update on the Dahej manufacturing site, a central pillar of its long-term strategy to move into technical manufacturing. The company is currently operating with formulations but plans to shift toward technical production. A pilot phase is set for December 2026, with full commercial technical production expected in 2027. This move is designed to enhance supply chain reliability and control over critical raw materials.
Global Strategy
Mahamaya Lifesciences currently operates in over 25 countries. The company is actively capitalizing on the global 'China+1' sourcing trend, positioning itself as a reliable alternative for international clients looking for flexible batch sizes and stable supply chains in the Middle East, Africa, ASEAN, and Latin America regions.
What to track next
Investors should closely monitor the progress of the Dahej facility. Successful execution of the pilot plant by December 2026 is critical, as it will likely determine the company's ability to drive further margin expansion and reduce reliance on external technical inputs by 2027.